Intestine Organoids Segment to Lead Overall Organoids Market During 2023–2031
According to our new research study on "Organoids Market Forecast to 2031 – COVID-19 Impact and Global Analysis – by Type, Application, Source, Type, and Method, and Geography," the market size is expected to grow from US$ 3.03 billion in 2023 to US$ 15.01 billion by 2031; it is projected to register a CAGR of 22.3% during 2023–2031. The organoids market growth is attributed to the increasing demand for tumor modeling & biobanking, and a surging adoption of personalized drugs. However, the dearth of skilled professionals and stringent safety regulations hinder the growth of the market. Key developments by companies are likely to offer opportunities for market growth.
Organoids are stem cell-derived, microscopic, self-organizing three-dimensional tissue cultures. These cultures can be designed to express certain features of an organ, such as the production of only particular cell types, or to mimic a significant portion of its complexity. Organoids are developed from stem cells, which are unbounded multiplicity cells that give rise to a variety of cell types in their offspring. Over the years, scientists have come up with the correct conditions to allow stem cells to follow their own genetic fate and self-organize into tiny structures that resemble miniature organs. Organoids can be as small as 5 mm, or they can be smaller than the breadth of a hair strand. The organoids market report emphasizes key factors impacting the market and showcases the developments of prominent players.
Organoids Market, by Region, 2023 (%)
Organoids Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Intestine, Liver, Stomach, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology Disease, Pathology of Infectious Disease, Regenerative Medicine, Drug Toxicity & Efficacy Testing, Drug Discovery & Personalized Medicine, and Others), Source (Pluripotent Stem Cells and Organ Specific Adult Stem Cell), Offering [Instruments (Devices and Equipment), Consumables (Sensors and Others), and Services], Method (Micropatterned Plates, Ultralow Attachment Plates, Hanging Drop, Microdroplet or Emulsion, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Organoids Market Size, Growth, Share by 2031
Download Free Sample
Source: The Insight Partners Analysis
Based on type, the organoids market is classified into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest organoids market share in 2023; it is estimated to register the highest CAGR during 2023–2031. Intestinal organoids are 3D models of the human intestinal epithelium that can be utilized in patient-specific in vitro research to investigate the properties of the intestinal epithelium. The prevalence of inflammatory bowel diseases (IBD) is rapidly increasing across developed and developing countries. IBDs such as Crohn's disease and ulcerative colitis are common worldwide. According to data by the European Federation of Crohn's & Ulcerative Colitis Association (EFCCA), published in May 2022, ~10 million people across the world live with IBDs. The data also stated that Crohn's disease or ulcerative colitis was common in the UK in 2022, with a rate of 1 in every 123 people. In terms of source, the organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cells.
Based on application, the market is segmented into developmental biology, infectious disease pathology, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held the largest organoids market share in 2023, and it is estimated to register the highest CAGR during 2023–2031. Developmental biology is the study of processes involved in the growth and development of multicellular organisms, which are controlled by their genes. Organoids developed from stem cells or tissues in culture can be converted into structures that resemble the in vivo anatomy and physiology of intact organs. Human organoid cultures can be used to study human development and model diseases with the same depth of analysis that is customary for research with nonhuman model organisms. Technological advancements in 3D bioprinting have shown a massive potential to facilitate organ development, as the time required for organoid culturing is much less than traditional tissue culture methods. Patient-derived human organoid studies may create new opportunities in the fields of tissue engineering and regenerative medicine, generating knowledge and tools for preclinical testing in drug development studies.
Combination of Organoids and Organ-on-a-Chip to Bring New Trends in Market in Coming Years
Technological advancements enabling the combination of organoids with organ-on-a-chip facilitate various applications of organoids in biological and biomedical fields, namely in disease modeling and clinical drug screening. Organoids and organ-on-a-chip, which serve as evolving pathological and human physiological in vitro models, have the potential to revolutionize the conventional paradigm of cancer research and produce real clinical benefits. The recent inclination in the collaborative application of organoids with organ-on-a-chip and 3D bioprinting enables the development of sophisticated cancer models to study underlying mechanisms of tumor-stroma interactions, multiorgan tumor metastasis, and cancer-microenvironment interactions. Organoid-on-a-chip, the incorporation of multiple organoids on a chip, exhibits the benefits of both organoid and organ-on-a-chip as well as provides a valuable tool to study multiorgan tumor metastases and cancer-microenvironment interactions. Technological advancements have enabled the development of brain organoids-on-chip, liver organoids-on-chip, intestine organoids-on-chip, and more. Organoid-on-a-chip is an emerging segment with much scope for improvement. Thus, with cooperative efforts from interdisciplinary researchers to reach the full utility of organoids in human biomedical studies, the combination of organoids and organ-on-a-chip is expected to bring new organoids market trends in the coming years.
Key players identified and evaluated while performing organoids market analysis are STEMCELL Technologies; Molecular Devices, LLC.; HUB Organoids B.V. (Hubrecht Organoid Technology); DefiniGEN; Organoid Therapeutics; Thermo Fisher Scientific Inc.; Corning Inc.; Merck KGaA; InSphero; ACRO Biosystems; and Bio-Techne Corporation.
The geographic scope of the organoids market report encompasses North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the market in 2023. The organoids market size in North America is expected to register a CAGR of 24.0% during 2023–2031. The market in Asia Pacific is expected to record the highest CAGR during the forecast period. The projected organoids market growth in the region during the forecast period is attributed to factors such as the increasing use of organoids, government efforts to raise awareness related to human organoids, supportive regulations for the development and commercialization of advanced human organoid products, and an upsurge in the funding for organoid research.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com